• Tovanor® Breezhaler®, which active substance is glycopyrronium bromide, is a long-acting anticholinergic bronchodilator for the maintenance treatment of COPD in adults.
• With this agreement Gebro Pharma enters the respiratory therapeutic area.
Barcelona, 23 February 2015- Gebro Pharma have signed an agreement with Novartis Farmacéutica for the commercialization of Tovanor® Breezhaler® in Spain, which active substance is glycopyrronium bromide.
Gebro Pharma will be responsible for the promotion and distribution of Tovanor Breezhaler (glycopyrronium bromide) on a local level, a long-acting anticholinergic bronchodilator administered once daily for the maintenance treatment of Chronic Obstructive Pulmonary Disease (COPD) in adults.
Tovanor Breezhaler is presented with the Breezhaler device (inhaler) and 30 hard capsules containing glycopyrronium bromide. Breezhaler device has been designed in order to facilitate the medication intake and the therapeutic adherence of COPD patients, with characteristics such as the low air flow resistance, the reliable feedback and the usability.
As stated by Gebro Pharma’s general director in Spain, Sergi Aulinas “This alliance allows us to add to our business franchises an excellent product, and to offer a cost-effective solution for the patient and for the health system.”
Chronic Obstructive Pulmonary Disease in Spain
Chronic Obstructive Pulmonary Disease (COPD) is defined as a respiratory disease essentially characterized by a chronic airflow limitation which is not totally reversible. It is usually manifested in the form of dyspnoea and it’s generally progressive. The airflow limitation is associated with an abnormal inflammatory response from the lungs to damaging particles and gases that can cause other symptoms such as chronic cough with or without expectoration.
Tobacco is the most common cause of COPD since it affects 15% of smokers; 13% of former smokers and 5% of people who have never smoked. Other causes, although less relevant, are genetic factors and pollution .
It is estimated that the disease affects over 210 million people in the world. In Spain it is calculated that it affects over 2 million people, of which 18,000 die every year, becoming the fifth cause of death in men and the seventh in women .
About Gebro Pharma
Laboratorios Gebro Pharma is a pharmaceutical company focused on the development and commercialization of prescription and hospital products. In Spain, Gebro started activities in 2002, based in Barcelona, with more than 120 employees. Laboratorios Gebro Pharma belongs to the Austrian pharmaceutical group Gebro Pharma GmbH, which for more than 60 years ago, deals with development, manufacturing and commercialization of pharmaceutical specialties.
Gebro Pharma is a benchmark in the areas of pain, rheumatology and urology, where it develops and commercializes a portfolio of innovative drugs, amongst which are Metoject®, a leading drug in the treatment of rheumatoid arthritis; Feliben®, buprenorphine transdermal patches for the treatment of severe chronic pain, or Kentera®, oxybutynin transdermal patches for the symptomatic treatment of urge incontinence.
For further information: www.gebro.es
For further information:
Grupo Inforpress
Laura Puig
+34 93 419 06 30
lpuig@inforpress.es
Help employers find you! Check out all the jobs and post your resume.
